Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Lunn"


3 mentions found


Staff at a conservation group captured the birth of 15 Burmese peacock softshell turtle hatchlings. Nyein Chan & Yae Aung / Fauna & FloraAs a result, Burmese peacock softshell turtles are one of the world's most endangered freshwater turtle species. An adult Burmese peacock softshell turtle (Nilssonia formosa) being released in Indawgyi. "Working with local communities will be key to our success in addressing the threats to the critically endangered Burmese peacock softshell turtle. We are already seeing the results of collaborating with communities to manage and protect key nesting sites and habitat," said Zau Lunn, Programme Manager, Freshwater and Marine, Fauna & Flora.
Persons: , Nyein Chan, Jeremy Holden, Fredric Janzen, Flora, Zau Lunn, Lunn Organizations: Service, Zoological Society, London's, Local, Flora International, Fauna & Flora International, & Flora, New York Times, Michigan State University, Fauna, UNESCO Biosphere Reserve Locations: Myanmar, East, Southeast Asia, Indawgyi, formosa
Now that they’re identified as Burmese peacock turtles, more research can begin. Other turtle species’ eggs, even in the Nilssonia genus, hatch after just two or three months. The total number of Burmese peacock turtles is unknown, but scientists suspect that their population may have declined by at least 80 percent over the past 90 years. While adult turtles are mostly invulnerable to predators, very few turtles survive from the egg and hatchling stages to adulthood, Dr. Platt said. That makes these Burmese peacock turtle babies all the more precious.
Persons: Zau Lunn, , Steven Platt, Platt, isn’t Organizations: Wildlife Conservation Society, International Union for Conservation
Credit Suisse upgraded Danish pharmaceutical company Novo Nordisk to outperform from neutral on Thursday, citing growth in its obesity and diabetes drugs. "Rx trends for both Ozempic and Wegovy YTD have been a major surprise and have significantly outperformed our expectations," he wrote. Now that Wegovy is back in supply, Credit Suisse had expected a potential slowdown in growth for Ozempic. Instead, while there has been a rise in new patients taking Wegovy, Ozempic is continuing to see growth, Dunn said. "Novo sees growth being driven by penetration in diabetes rather than off-label obesity use, which is backed up by the fact the Ozempic growth has accelerated despite re-supply of Wegovy for Obesity," he said.
Total: 3